- Home
- MDAI vs AKTX Comparison
MDAI vs AKTX Comparison
Compare MDAI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- AKTX
- Stock Information
- Founded
- MDAI 2013
- AKTX N/A
- Country
- MDAI United States
- AKTX United States
- Employees
- MDAI N/A
- AKTX N/A
- Industry
- MDAI Medical/Dental Instruments
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- AKTX Health Care
- Exchange
- MDAI Nasdaq
- AKTX Nasdaq
- Market Cap
- MDAI 51.5M
- AKTX 41.8M
- IPO Year
- MDAI N/A
- AKTX N/A
- Fundamental
- Price
- MDAI $2.12
- AKTX $1.12
- Analyst Decision
- MDAI Strong Buy
- AKTX
- Analyst Count
- MDAI 2
- AKTX 0
- Target Price
- MDAI $4.75
- AKTX N/A
- AVG Volume (30 Days)
- MDAI 455.5K
- AKTX 25.4K
- Earning Date
- MDAI 08-11-2025
- AKTX 08-18-2025
- Dividend Yield
- MDAI N/A
- AKTX N/A
- EPS Growth
- MDAI N/A
- AKTX N/A
- EPS
- MDAI N/A
- AKTX N/A
- Revenue
- MDAI $29,962,000.00
- AKTX N/A
- Revenue This Year
- MDAI N/A
- AKTX N/A
- Revenue Next Year
- MDAI $56.05
- AKTX N/A
- P/E Ratio
- MDAI N/A
- AKTX N/A
- Revenue Growth
- MDAI 55.21
- AKTX N/A
- 52 Week Low
- MDAI $0.82
- AKTX $0.85
- 52 Week High
- MDAI $3.25
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- MDAI 67.16
- AKTX 47.22
- Support Level
- MDAI $1.97
- AKTX $1.08
- Resistance Level
- MDAI $2.28
- AKTX $1.25
- Average True Range (ATR)
- MDAI 0.16
- AKTX 0.08
- MACD
- MDAI 0.01
- AKTX -0.01
- Stochastic Oscillator
- MDAI 82.81
- AKTX 39.71
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.